000			04172nam a22003974u 4500
001			10.1002/9781119824572
003			Wiley
005			20251030120303.0
007			cr nn 008mam|a
008			240205t2024||||xxu fs| |0|| 0|eng||
020			_a9781119824572 _qelectronic
024	7		_a10.1002/9781119824572 _2doi
041			_aeng
245	0	0	_aPrecision Cancer Therapies vol 2 ‐ Immunologic Approaches for the Treatment of Lymphoid Malignancies ‐ From Concept to Practice _h[electronic resource] _cEdited by Owen A. O'Connor, Stephen M. Ansell, John G. Gribben.
250			_a1
260			_bWiley _c2024
264		1	_bWiley _c2024
300			_a496pp.;
336			_atext _btxt _2rdacontent
337			_acomputer _bc _2rdamedia
338			_aonline resource _bcr _2rdacarrier
347			_atext file _2rdaft
347			_bPDF
520			_aPresents timely and authoritative information on the development of precision cancer therapies as applied to hematologic malignancies The Precision Cancer Therapies series focuses on how to understand and translate fundamental basic science into information that can be directly applied to patients to advance care. Each volume of the series integrates the relevant biological concepts and principles necessary for translating this science to practitioners of this science. Precision Cancer Therapies, Volume Two, focuses on sophisticated immunotherapies targeting cancers affecting the blood, bone marrow, and lymph nodes. Edited and authored by the foremost authorities in the field, this comprehensive reference text covers targeting of cell surface receptors, antibody-drug conjugates (ADC), targeting immune checkpoint, targeting macrophages, EBV-directed immunotherapies, tumor-associated antigens (TAA), and chimeric antigen receptor T-cells (CAR-T). Divided into nine sections, Volume Two includes an overview of the history of immunotherapy development in cancer, as well as a concluding section addressing the mechanistic basis and role of immunomodulatory drugs, analytical tools to quantitate immune-mediated effects, and other topics in immunotherapy. Chapters on specific therapeutics or therapeutic classes include a basic explanation of the underlying pathway and target, the pharmacology of the drug/class, relevant preclinical and clinical data, and discussion of clinical management and potential predictive biomarkers of response. This book also: Delivers a definitive, state-of-the-art review of the relevant biology and its importance in the broader context of cancer biology Focuses on agents that mediate cell killing in lymphoma through a variety of immunologic mechanisms Covers FDA-approved drugs and their indications, as well as drugs currently in development Provides information on monotherapy and combination therapy, summary tables of trials, and discussion of toxicity and efficacy Includes boxed sections highlighting major unique points about the information in the chapter Precision Cancer Therapies, Volume Two: Immunologic Approaches for the Treatment of Lymphoid Malignancies, From Concept to Practice is an indispensable resource for medical, scientific, and allied medical professionals, advanced students, and interested general readers with background knowledge in the subject.
650		4	_aMedical Oncology _964358
650		4	_aHematology _976927
653	0	0	_aimmunotherapy hematologic malignancies; lymphoid malignancies pharmacology; lymphoid malignancies ADC; immune checkpoint lymphoma; EBV immunotherapies; T-CELLS lymphoma; therapeutic targeting; CAR-T Cells lymphomas; EBV immunotherapies
700	1		_aO'Connor, Owen A. _4edt _991091
700	1		_aAnsell, Stephen M. _4edt _991092
700	1		_aGribben, John G. _4edt _991093
776	0	8	_iPrinted edition: _z9781119824541
856	4	0	_uhttps://doi.org/10.1002/9781119824572 _aWiley Online Library
856	4	0	_uhttps://onlinelibrary.wiley.com/action/showBook?doi=10.1002%2F9781119824572 _aWiley Online Library
856	4	2	_3Cover Image _uhttps://onlinelibrary.wiley.com/cms/asset/0bb0f673-ed08-42a4-9253-c0e908091a42/9781119824572.cover.gif _aWiley Online Library
999			_c66861 _d66861